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Abstract
Since organic acid analysis in urine with gaschromatography-mass spectrometry (GC-MS) is a time-consuming technique, we
developed a new liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF/MS) method to replace the
classical analysis for diagnosis of inborn errors of metabolism (IEM). Sample preparation is simple and experimental time short.
Targeted mass extraction and automatic calculation of z-scores generated profiles characteristic for the IEMs in our panel
consisting of 71 biomarkers for defects in amino acids, neurotransmitters, fatty acids, purine, and pyrimidine metabolism as
well as other disorders. In addition, four medication-related metabolites were included in the panel. The method was validated to
meet Dutch NEN-EN-ISO 15189 standards. Cross validation of 24 organic acids from 28 urine samples of the ERNDIM scheme
showed superiority of the UPLC-QTOF/MS method over the GC-MS method. We applied our method to 99 patient urine
samples with 32 different IEMs, and 88 control samples. All IEMs were unambiguously established/diagnosed using this new
QTOF method by evaluation of the panel of 71 biomarkers. In conclusion, we present a LC-QTOF/MS method for fast and
accurate quantitative organic acid analysis which facilitates screening of patients for IEMs. Extension of the panel of metabolites
is easy which makes this application a promising technique in metabolic diagnostics/laboratories.
Introduction
Urinary organic acid analysis is a pivotal technique in selec-
tive screening for inborn errors of metabolism (IEMs) (Tanaka
et al 1980; de Almeida and Duran 2014). The current state of
the art relies on gas-chromatography coupled to mass spec-
trometry (GC-MS) of derivatized compounds. By its nature,
the literally hundreds of organic acids present in human urine,
endogenous as well as microbiome, drugs and other
xenobiotic-derived metabolites (Blau et al 2014), can be de-
tected by GC-MS. In fact, GC-MS analysis is the forerunner
of untargeted metabolomics analysis as we nowadays envi-
sion it.
GC-MS has several advantages. It has high separation effi-
ciency of metabolites, high specificity and sensitivity, few ma-
trix effects, and broadly covered mass spectra libraries for iden-
tification of metabolites of interest are widely available
(Pasikanti et al 2008). Disadvantages are clearly present since
organic acids are not volatile and require organic solvent ex-
traction and derivatization prior to GC-MS analysis. This
makes the procedure laborious, and compared to underivatized
tandem-mass spectrometry methods, time-consuming in terms
of analytical run-time. Moreover, a relatively large sample
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volume is needed, despite efforts to increase throughput and
reduce sample volume (Nakagawa et al 2010).
High resolution proton nuclear magnetic resonance (NMR)
spectroscopy is a good alternative for organic acid analysis
(and even broader IEM screening) with minimal sample prep-
aration and a short experimental time. NMR spectroscopy did,
however, not evolve in common IEM screening because of
financial constraints and its relatively low sensitivity in the
low millimolar range (Moolenaar et al 2003). Alternative liq-
uid chromatography (LC)-quantitative hyphenated tandem
mass spectrometry (MS/MS) techniques have been developed
that allow high-throughput (Want et al 2010; Bouatra et al
2013). LC-MS/MS has outstanding sensitivity (in low
nanomolar range) and specificity but only targeted metabo-
lites, i.e., those a-priori selected in the method, are detected
and quantified. The relatively recent introduction of high-
resolution (HR) mass spectrometry in the form of time-of
flight (TOF) MS and Orbitrap MS specificity allowed a major
breakthrough. LC-HR MS combines the analytical power of
LC-MS/MS with the unbiased quality of classical GC-MS,
and thus enables not only the quantification of target metabo-
lites, but also facilitates untargeted metabolite screening. Until
now, LC-HR MS, including LC-QTOF/MS that combined
with a quadrupole (Q), has been widely deployed in research
settings (Paglia et al 2012), including inborn errors of metab-
olism (Wikoff et al 2007). Apart from a qualitative untargeted
metabolomics approach (Miller et al 2015), no quantitative
application suitable for routine diagnostic setting has been
reported in the inborn errors of metabolism (IEM) field.
Here, we present our newly developed LC-QTOF/MS
method for the quantitative analysis of urinary organic acids.
This method covers a panel of critical biomarkers targeting
defects in branched-chain amino acid-, lysine- and trypto-
phan-, aromatic amino acid-, neurotransmitter-, fatty acid-
and pyrimidine metabolism as well as disorders in the Krebs
cycle and urea cycle, amino acylase deficiencies and various
other disorders. In addition, four medication-related metabo-
lites were included in the panel, to allow discrimination be-
tween metabolic defects and medication. Analytical and diag-
nostic suitability were demonstrated in a cohort of individual
urine samples, including proven IEMs. To expedite clinical
interpretation we introduced z-score value plots. Our results
demonstrate the suitability of this new method in the routine
setting of selective metabolic screening.
Material and methods
Samples collection
All procedures followed were in accordance with the ethical
standards of the BHuman tissue and medical research- Code of
Conduct for Responsible Use^ by Dutch Federation of
Biomedical Scientific Societies.
Clinical validation samples Random urine specimens used in
this study were selected from multiple laboratories. The spec-
imens without a diagnosis (N = 88) used in this study were
selected from the archive of the Maastricht Laboratory of
Clinical Genetics. Samples were analyzed using the presently
described method 1–2 years after routine diagnostic work-up
and stored at −20 °C. Only urine samples from patients with-
out a confirmed inborn error of metabolism (IEM) or any other
biochemical finding or condition that was likely to influence
the biochemical read-out were included. Samples of patients
(N = 99) with confirmed diagnoses of IEM were included as
positive controls. Detailed information on the clinical situation
or treatment was not always available. These samples were
from the archives of Maastricht Laboratory of Clinical
Genetics, Translational Metabolic Laboratory, Radboud
University Medical Centre, Nijmegen and from the archives
of the Heidelberg and Sheffield qualitative organic acid as-
sessment schemes of ERNDIM (European Research
Network for evaluation and improvement of screening, diag-
nosis and treatment of Inherited disorders of Metabolism;
www.erndim.org).
Method comparison samplesWe used 28 urine samples of the
ERNDIM quantitative organic acids quality assurance scheme
from the period 2009–2015 for method cross validation.
Chemicals, standards, and internal standards
All mobile phase solutions were prepared with UPLC-MS
grade solvents of water, formic acid, and acetonitrile from
Biosolve (Valkenswaard, the Netherlands). Supplemental
Table S1 shows the 68 organic acid standards and 19 internal
standards (ISTD) and their source. In the case of 2-
pyrroloylglycine, hawkinsin, and 3-hydroxysebacic acid,
urine samples of diagnosed patients with hyperprolinemia
type II (HYRPRO2, OMIM #239510), hawkinsinuria
(OMIM #140350), and long-chain 3-hydroxyl-CoA dehydro-
genase deficiency (LCADD, OMIM #609016), respectively,
served as surrogate standards. The four metabolites of medi-
cation were based on urine samples of patients using paracet-
a m o l ( a c e t a m i n o p h e n , g l u c u r o n i d e , a n d
acetaminophensulphate), levetiracetam, and valproic acid
(valproic acid glucuronide).
LC-QTOF/MS method
Frozen urine samples were thawed at 37 °C and homogenized
by vortex mixing; 25 μl urine adjusted to a creatinine concen-
tration of 0–2 mM was mixed with 350 μL 0.1% v/v formic
acid in water and 25 μL ISTD mixture. The samples were
416 J Inherit Metab Dis (2018) 41:415–424
analyzed on an LC-QTOF/MS system (Agilent Technologies,
Amstelveen, the Netherlands) that consisted of an Infinity II
1290 UHPLC coupled to a 6550 iFunnel QTOF equipped
with an electrospray ionization source. The temperature in
the multi-sampler was set at 4 °C. LC-separation was per-
formed on an Acquity C18 column UPLC HSS T3 1.8 μm
2.1 × 100 mm with Acquity VanGuard PreColumn UPLC
HSS T3; 2.1 × 5 mm (Waters, Manchester, UK) at 22 °C.
The injection volume was 2 μL, followed by standard needle
wash. The mobile phases for the reversed-phase (RP)-LC con-
sist of solution A) 0.1% v/v formic acid in water and solution
B) 0.1% formic acid in 95% acetonitril/5% water. The gradi-
ent program of the 35 min-cycle is described in Suppl.
Table S2. The MS was tuned for low mass range (up to
1700 m/z) at high resolution slicer mode + 2G Hz extended
dynamic range, and run in the negativemode for full scan with
parameters listed in Suppl. Table S3. Agilent reference mass
solution (containing reference compounds with m/z 112.9856
and m/z 1033.9881) was infused into the MS via a 1260
isocratic pump (Agilent) for continuous mass correction.
Calibration mixture stock solutions of 68 analytes were
prepared and stored at −80 °C. In each batch, 6-point calibra-
tion curves were made with freshly prepared dilutions
(Table 1). The quality of the batch was continuously moni-
tored with a quality control (QC) sample with known amounts
of 57 analytes. A QC sample and blank were injected at the
start and after every 24th sample throughout the analytical
workflow.
Data analysis and statistics
MassHunter workstation software (Agilent) Acquisition B.06
and Quantitative Analysis for Q-TOF B.07 were used for MS
data acquisition and analysis. The monitored ions and their
retention times, established with standards or patients sam-
ples, and the ISTD of each analyte are listed in Table 1. The
peak area was used for quantification. Each analyte was abso-
lutely quantified based on its own standard calibration curve,
except the seven aforementioned analytes based on patients’
urine, of which concentrations were calculated with a relative
ISTD method assuming the analyte has the same response
factor as its ISTD. All concentrations were normalized to
urine creatinine concentrations obtained from clinical chemis-
try lab (Jaffe method).
Z-scores were calculated by comparing analyte log trans-
formed values to the associated mean and standard deviation
found in a control cohort without a diagnosed IEM (n = 46) in
two age groups (0–2 years and >2 years). Missing values and
values below the estimated limit of detection (LOD, concen-
tration equivalent to 3 * S/N) were imputed with LOD before
log transformation. For the analytes that were not detected in
normal urines, SD was set as 0.774 to report a z-score value of
3 when the measurement result is five times the LOD.
Method analytical validation
The method was validated according to our internal validation
procedure for quantitative methods based on the Dutch NEN-
EN-ISO 15189 guide BMedical Laboratories-Requirements
for quality and competence^ (Nederlands Normalisatie-
instituut (NEN) 2012).
Method cross validation
Urine samples from the ERNDIMQuantitative Organic Acids
External Quality Assessment Scheme were analyzed by GC-
MS and the UPLC-QTOF/MS method. The results from GC-
MS analyses as performed in the ERNDIM scheme were used
as a reference for the new method. The results of the medians
of participants in the ERNDIM scheme were retrieved from
ERNDIM archive; 98% of the participants used GC-MS
(Peters et al 2016).
We compared the results of 24 spiked analytes in 28
ERNDIM samples on recovery and linearity (Martens and
Weykamp 2016). Method differences were assessed per ana-
lyte by t-test or Mann-Whitney test when proper. A P-value
<0.05 was considered to be significant. We also applied
Passing-Bablok regression analysis (Passing and Bablok
1983). The above analyses were done in R environment, and
with method comparison regression (MCR) package
(Manuilova et al 2014; R Core Team 2016).
Results
Analytical characteristics of the LC-QTOF/MS method
The UHPLC coupled QTOF/MS method was able to separate
and identify 74 analytes. The 2- and 3-hydroxyadipic acid
isomers could not be resolved due to identical retention times
and were therefore analyzed as one combined signal. Adipic
acid and 3-methylglutaric acid have the same mass and com-
parable hydrophobicity. At normal physiological conditions,
concentrations of both metabolites are low and there is a
0.05 min difference in retention time allowing adequate dis-
tinction. At pathological levels, however, the peak of the bio-
marker compound overwhelms another one. We need to com-
bine the profile of biomarks and clinical presentation to re-
solve the identity of the peak. The suboptimal peak shapes of
2-methylcitric acid, succinylacetone (Suppl. Figure), citric ac-
id, and oxoadipic acid hampered correct quantification, but
analogue isotopic internal standards corrected for that to some
extent.
Linearity and recovery Linear calibration curves (R2 > 0.98)
were obtained in water and urine for all 68 analytes
(Table 1). The recovery was 100 ± 15% for the vast majority
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Table 1 Targeted biomarker panel
No. Designation Name HMDB ID [M-H]- ion, m/z RT, min ISTD Calibration range, μM
Disease markers
1 Acetoacetic acid HMDB00060 101.0244 1.90 D3-propionylglycine 15.6–249.6
2 N- Acetylglutamine HMDB06029 187.0724 1.18 13C5-oxoglutaric acid 9.4–150.1
3 N- Acetyl-L-alanine HMDB00766 130.0510 2.62 13C4–3-hydroxybutyric acid 9.9–158.5
4 N- Acetyl-L-aspartic acid HMDB00812 174.0408 1.25 D3-propionylglycine 8.0–128.5
5 N- Acetyl-L-methionine HMDB11745 190.0543 5.19 D4-adipic acid 10.0–159.5
6 Adipic acid HMDB00448 145.0506 4.93 D4-adipic acid 12.5–200.4
7 Argininosuccinic acid HMDB00052 289.1154 0.72 D2-glycolic acid 6.9–111.0
8 N- Butyrylglycine HMDB00808 144.0666 4.22 D4-glutaric acid 0.5–7.9
9 Citric acid HMDB00094 191.0197 1.88 D4-citric acid 331.0–5290.0
10 Ethylmalonic acid HMDB00622 131.035 4.58 D5-ethylmalonic acid 8.7–138.6
11 Fumaric acid HMDB00134 115.0037 2.06 D3-propionylglycine 8.3–133.3
12 Glutaric acid HMDB00661 131.035 4.11 D4-glutaric acid 8.6–138.4
13 Glyceric acid HMDB00139/HMDB06372 105.0193 0.76 D3-glyceric acid 8.0–128.2
14 Glycolic acid HMDB00115 75.0088 0.78 D2-glycolic acid 19.9–318.4
15 Hawkinsin HMDB02354 291.0777 1.16 D3-malic acid ▬
16 Hexanoylglycine HMDB00701 172.0979 6.86 D3-hexanoylglycine 0.4–6.7
17 Homogentisic acid HMDB00130 167.035 4.54 D4-sebacic acid 2.4–38.0
18 Homovanillic acid HMDB00118 181.0506 6.14 D3-hexanoylglycine 6.2–99.7
19 Hydantoin-5-propionic acid HMDB01212 171.0411 3.05 D3-methylmalonic acid 5.1–82.0
20 2- Hydroxy-3-methylbutyric acid HMDB00407 117.0557 4.76 D4-adipic acid 6.8–108.8
21 3- Hydroxy-3-methylglutaric acid HMDB00355 161.0455 3.68 D3–3-hydroxy-3-methyl-glutaric acid 10.8–172.8
22 2- Hydroxy-3-methylpentanoic acid HMDB00317 131.0714 6.03 D4-sebacic acid 6.1–97.0
23 2- & 3- Hydroxyadipic acid HMDB00321/HMDB00345 161.0455 3.73 D4-adipic acid 5.3–84.7
24 3- Hydroxybutyric acid HMDB00357 103.0401 2.56 13C4–3-hydroxybutyric acid 8.0–128.2
25 4- Hydroxybutyric acid HMDB00710 103.0401 1.93 13C4–3-hydroxybutyric acid 8.0–128.2
26 3- Hydroxyglutaric acid HMDB00428 147.0299 1.71 D3-propionylglycine 7.3–116.4
27 2- Hydroxyglutaric acid HMDB00606/HMDB00694 147.0299 1.40 D3-propionylglycine 7.3–116.4
28 5- Hydroxyindoleacetic acid HMDB00763 190.051 5.71 D3-hexanoylglycine 9.1–146.0
29 3- Hydroxyisobutyric acid HMDB00336/HMDB00023 103.0401 2.90 13C4–3-hydroxybutyric acid 12.2–195.4
30 2- Hydroxyisocaproic acid HMDB00746 131.0714 6.15 D4-adipic acid 8.8–141.3
31 3- Hydroxyisovaleric acid HMDB00754 117.0557 4.13 D4-glutaric acid 7.6–122.0
32 Ortho- Hydroxyphenylacetic acid HMDB00669 151.0401 6.64 D3-hexanoylglycine 8.1–129.6
33 4- Hydroxyphenylacetic acid HMDB00020 151.0401 5.81 D3-hexanoylglycine 8.1–129.6
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Table 1 (continued)
No. Designation Name HMDB ID [M-H]- ion, m/z RT, min ISTD Calibration range, μM
34 4- Hydroxyphenyllactic acid HMDB00755 181.0506 5.17 D4-adipic acid 7.3–116.0
35 4- Hydroxyphenylpyruvic acid HMDB00707 179.035 4.62 D4-adipic acid 8.4–135.1
36 3- Hydroxypropionic acid HMBD00700 59.0133* 1.18 13C3-lactic acid 6.9–111.0
37 3- Hydroxysebacic acid HMDB00350 217.1081 6.69 D4-sebacic acid ▬
38 Isobutyrylglycine HMDB00730 144.0666 4.12 D4-adipic acid 0.4–5.7
39 Isovalerylglycine HMDB00678 158.0823 5.16 D3-hexanoylglycine 0.7–11.3
40 alpha- Ketoisovaleric acid HMDB00019 115.0401 3.81 D4-adipic acid 8.0–128.1
41 Lactic acid HMDB00190 89.0244 1.18 13C3-lactic acid 50.3–804.2
42 Malic acid HMDB00744 133.0142 1.04 D3-malic acid 7.9–125.7
43 Malonic acid HMDB00691 103.0037 1.18 D3-propionylglycine 7.1–113.7
44 3- Methyl-2-oxovaleric acid HMDB00491 129.0557 5.25 D4-adipic acid 8.5–135.3
45 2- Methyl-3-hydroxybutyric acid HMDB00354 117.0557 4.40 D4-adipic acid 7.1–114.0
46 3- Methyladipic acid HMDB00555 159.0663 5.76 D4-adipic acid 7.5–120.6
47 2- Methylbutyrylglycine HMDB00339 158.0823 5.03 D3-hexanoylglycine 0.7–11.0
48 2- Methylcitric acid HMDB00379 205.0354 3.92 D3-methyl citric acid 7.9–126.0
49 3- Methylcrotonylglycine HMDB00459 156.0666 5.17 D3-hexanoylglycine 0.6–9.0
50 3- Methylglutaconic acid HMDB00522 99.0452 * 4.84 D4-adipic acid 7.9–125.8
51 3- Methylglutaric acid HMDB00752 145.0506 5.00 D4-adipic acid 8.8–141.6
52 Methylmalonic acid HMDB00202 117.0193 2.89 D3-methylmalonic acid 8.1–128.9
53 Methylsuccinic acid HMDB01844 131.035 4.49 D5-ethylmalonic acid 5.1–81.0
54 Mevalonic acid HMDB00227 147.0663 3.15 D3-methylmalonic acid 13.0–210.0
55 Orotic acid HMDB00226 155.0098 1.18 D2-glycolic acid 6.7–107.1
56 Oxoadipic acid HMDB00225 159.0299 2.34 D4-sebacic acid 8.1–129.9
57 Oxoglutaric acid HMDB00208 145.0142 1.19 13C5-oxoglutaric acid 20.2–323.0
58 3- Phenyllactic acid HMDB00748 165.0557 6.95 D3-hexanoylglycine 7.2–114.5
59 Phenylpropionylglycine HMDB00860 206.0823 7.40 D3-hexanoylglycine 0.4–6.1
60 Propionylglycine HMDB00783 130.051 2.33 D3-propionylglycine 0.5–8.6
61 Pyroglutamic acid HMDB00267 128.0353 1.84 D5-pyroglutamic acid 6.2–99.8
62 2- Pyrroloylglycine HMDB59778 167.0462 4.61 D5-ethylmalonic acid ▬
63 Pyruvic acid HMDB00243 87.0088 0.91 13C3-pyruvic acid 6.1–97.2
64 Sebacic acid HMDB00792 201.1132 9.05 D4-sebacic acid 1.6–25.6
65 Suberic acid HMDB00893 173.0819 6.85 D4-sebacic acid 5.5–88.0
66 Suberylglycine HMDB00953 230.1034 5.68 D3-hexanoylglycine 0.4–6.3
67 Succinic acid HMDB00254 117.0193 2.55 D3-methylmalonic acid 31.0–495.6
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of analytes (63/68) in urine. For 2-methylcitric acid,
acetoacetic acid, 4-hydroxybutyric acid, malonic acid, and
pyroglutamic acid recovery was out of this range. For 2-
methylcitric acid, acetoacetic acid, and malonic acid this can
be explained by the chromatographic peak shape. Detection of
4-hydroxybutyric acid and pyroglutamic acid was complicat-
ed by ion suppression which could not be completely
corrected for by using alternative internal standards.
Limits of detection and quantification The majority of the
analytes had an estimated limit of quantification (LOQ, con-
centration equivalent to S/N > 10) < 3 μmol/l. Succinic acid,
oxoglutaric acid, ethylmalonic acid, 2-oxovaleric acid, 2-
methyl-3-hydroxybutyric acid, 4-hydroxyphenylpyruvic acid,
fumaric acid, glycolic acid, 3-methylglutaconic acid, malic
acid, oxoadipic acid, 3-hydroxyisobutyric acid, 3-
hydroxybutyric acid, succinylacetone, pyruvic acid, and
methylmalonic acid had a LOQ ≤ 15 μmol/l. Three com-
pounds had a higher LOQ, i.e., 4-hydroxybutyric acid
(18 μmol/l), malonic acid (21 μmol/l), and acetoacetic acid
(69 μmol/l).
Within- and between-run variation Within-run variation was
satisfactory for all analytes in urine, the coefficient of variation
was ≤10% for the vast majority of compounds. The coefficient
of variation was slightly higher for lactic acid (11%), 2-
methylcitric acid (12%), malic acid (12%), and mevalonic
acid (23%). For 2-methylcitric acid and malic acid the higher
variation is explained by poor peak-shape, whereas mevalonic
acid is unstable in the acid environment.
The between-run variation was satisfactory at low (CV <
20%) and for high calibration levels (CV < 10%) for the ma-
jority of compounds. For acetoacetic acid the CV was 13% at
93 μM; for 2-methylcitric acid CV 14% at 88 μM, poor peak-
shape being the main explanation.
1. Comparison and correlation between GC-MS and
LC-QTOF/MS methods
The results on 24 organic acids in 28 samples from the
ERNDIM quantitative organic acids scheme were used to
compare the GC-MS and LC-QTOF/MS methods
(Fig. 1). An acceptable recovery for an individual metab-
olite was defined as a recovery between 80 and 120%. For
the LC-QTOF/MS method 20/24 analytes showed an ac-
ceptable recovery which was similar to medians of all
participating labs in the original ERNDIM scheme (21/
24) (Fig. 1). LC-QTOF/MS had significantly improved
recovery for: pyroglutamic acid, tiglylglycine, and 3-
hydroxyisobutyric acid. For oxoglutaric acid and meva-
lonic acid, the LC-QTOF/MS recovery was below 80%
but still satisfactory for diagnostic purposes. Both GC-MS
(medians of all labs) and LC-QTOF/MS methods had
excellent linearities for all 24 analytes (Suppl. Table s4).T
a
b
le
1
(c
o
n
ti
n
u
ed
)
N
o
.
D
es
ig
n
at
io
n
N
am
e
H
M
D
B
ID
[M
-H
]-
io
n
,
m
/z
R
T
,
m
in
IS
T
D
C
al
ib
ra
ti
o
n
ra
n
g
e,
μ
M
6
8
S
u
cc
in
y
la
ce
to
n
e
H
M
D
B
0
0
6
3
5
1
5
7
.0
5
0
6
4
.5
0
1
3
C
5
-S
u
cc
in
y
l
ac
et
o
n
6
.7
–
1
0
7
.5
6
9
T
ig
ly
lg
ly
ci
n
e
H
M
D
B
0
0
9
5
9
1
5
6
.0
6
6
6
5
.0
7
D
3
-h
ex
an
o
y
lg
ly
ci
n
e
0
.9
–
1
4
.3
7
0
V
an
il
la
ct
ic
ac
id
H
M
D
B
0
0
9
1
3
2
11
.0
6
1
2
5
.5
1
D
4
-a
d
ip
ic
ac
id
7
.7
–
1
2
3
.4
7
1
V
an
il
ly
lm
an
d
el
ic
ac
id
H
M
D
B
0
0
2
9
1
1
9
7
.0
4
5
5
4
.0
5
D
4
-g
lu
ta
ri
c
ac
id
8
.6
–
1
3
8
.1
M
ed
ic
a
ti
o
n
m
a
rk
er
s
7
2
A
ce
ta
m
in
o
p
h
en
g
lu
cu
ro
n
id
e
H
M
D
B
1
0
3
1
6
3
2
6
.0
8
8
1
4
.1
9
D
4
-g
lu
ta
ri
c
ac
id
▬
7
3
A
ce
ta
m
in
o
p
h
en
su
lp
h
at
e
H
M
D
B
5
9
9
11
2
3
0
.0
1
2
9
4
.6
2
D
5
-e
th
y
lm
al
o
n
ic
ac
id
▬
7
4
L
ev
et
ir
ac
et
am
H
M
D
B
1
5
3
3
3
2
0
2
.0
7
2
1
4
.5
4
D
5
-e
th
y
lm
al
o
n
ic
ac
id
▬
7
5
V
al
p
ro
ic
ac
id
g
lu
cu
ro
n
id
e
H
M
D
B
0
0
9
0
1
3
1
9
.1
3
9
8
9
.0
5
D
4
-s
eb
ac
ic
ac
id
▬
N
o
te
:
*
in
[M
-H
]-
io
n
in
d
ic
at
es
u
se
d
fr
ag
m
en
t
io
n
th
at
co
m
es
fr
o
m
in
so
u
rc
e
fr
ag
m
en
ta
ti
o
n
420 J Inherit Metab Dis (2018) 41:415–424
Passing-Bablok regression analysis indicated that the LC-
QTOF/MS and the GC-MS (median of all labs) methods
were highly correlated and comparable. Mevalonic acid,
oxoglutaric acid, 3-hydroxyisobutyric acid, pyroglutamic
acid, and tiglylglycine showed a significant difference
with a slope out of range 0.8–1.2 (Suppl. Table S4).
2. Clinical validation of the LC-QTOF/MS methods
In the clinical validation, we analyzed 99 diagnostic sam-
ples of patients with an IEM (32 different IEMs included)
and 88 control samples. Figure 2 is a summary of the z-
scores on critical biomarkers for the 32 different IEM.
Most IEM were easily recognized with z-scores of bio-
markers clearly >2.5 in the z-score profile. In our daily prac-
tice, the actual concentrations are considered in addition to
the z-scores profile. In all control urine samples, the majority
of the biomarkers had z-scores between −2.5 to 2.5. Figure 3
shows representative z-score profiles of patients with
isovaleric aciduria (IVA, OMIM #243500), medium chain
acyl-CoA dehydrogenase deficiency (MCADD, OMIM
#201450), propionic aciduria (PA, OMIM #606054),
glutaric aciduria type 1 (GA I, OMIM #231670), and
methylmalonic aciduria (MMA (mut0), OMIM #251000).
For maple syrup urine disease (MSUD, OMIM #248600), 2-
hydroxy-3-methylpentanoic acid and 2-hydroxy-3-
methylbutyric acidwere themost discriminating biomarkerswith
z-scores >10 in all patients. Five patients with a glutaric aciduria
type I (GA I, OMIM #231670) were easily diagnosed based on
elevated concentrations of 3-hydroxy-glutaric acid (z-score >
10); four of them also had significantly elevated glutaric acid.
Only one GA I patient had a normal excretion of glutaric acid.
Five patients with glutaric aciduria type II (GA II, multiple
acyl-CoA dehydrogenase deficiency (MADD), OMIM
#231680) presented with an increased excretion of
ethylmalonic acid (EMA), glycine conjugated as well as di-
carboxylic acids. Glutaric acid and 2-hydroxyglutaric acid
were not consistently elevated in all three cases. A mild
MADD case even presented with non-significant excretion
of 2-hydroxyglutaric acid (z-score 2.5) but with a clear in-
crease in both EMA and dicarboxylic acids. The excretion of
EMA in MADD is comparable in z-score to short-chain acyl-
CoA dehydrogenase deficiency (SCADD, OMIM #201470).
In all MCADD patients, phenylpropionylglycine,
hexanoylglycine, and suberylglycine were significantly in-
creased with z-scores >5.0.
One patient with 5-oxoprolinuria (pyroglutamic aciduria,
OMIM #266130) was included and had a high excretion of
pyroglutamic acid (z-score > 10). The absence of paracetamol
me t a b o l i t e s a c e t am i n o p h e n g l u c u r o n i d e a n d
acetaminophensulphate excluded medication-related changes.
In other patients within our sample panel on paracetamol in-
dicated by the presence of these two medication-related me-
tabolites, only a minor increase of pyroglutamic acid (z-score
2.5–5.0) (data not shown) was observed.
Discussion
Urine organic acid analysis is a pivotal part in the diagnostic
workup of inborn errors of metabolism (IEM). We developed a
LC-QTOF/MSmethod for the quantification of 71metabolites in
urine covering all disorders classically identified throughGC-MS
analysis of organic acids. This targeted analyses is aimed at
Fig. 1 Comparison of the general
GC-MS method with our new
LC-QTOF/MS on 28 ERNDIM
QC urine samples containing 24
spiked analytes
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finding most organic acidurias in a fast manner, with the limita-
tion that some IEM classically detected in GC-MS analysis, such
as glycerol kinase deficiency, are not detected. Obviously, in case
of strong clinical suspicion additional analyses are required in
these cases. However, our method can be easily expanded by
adding more relevant biomarkers for other IEM. The method
was validated according to Dutch NEN-EN-ISO 15189 stan-
dards underlining its fit for purpose in the routine setting of a
specialized diagnostic laboratory in the field of IEM.
Performance characteristics (i.e., recovery) of our new analytical
UHPLC-QTOF/MS assay were comparable or even superior to
the classical GC-MS analysis. Cross validation showed on line-
arities and recoveries that our results compared well to that of the
median of all labs for the GC-MSmethod. The targeted approach
with internal standards makes our method robust. In addition,
simple sample preparation and short time fromunprocessed urine
sample-to-authorized lab result of an individual sample (< 3–4 h)
are clear benefits for the LC-QTOF/MS assay. However, for two
metabolites, i.e., oxoglutaric acid and mevalonic acid, LC-
QTOF/MS had a worse recovery than the classical assay. Two
cases of classical mevalonic aciduria (MEVA, OMIM #610377)
were easily diagnosed based on z-score profiles with abnormal
mevalonic acid. Hyper-IgD syndrome (OMIM #260920) diag-
nostics depends on detecting more subtle increased excretion of
mevalonic acid especially in periods of episodic fever (Prietsch
et al 2003). We measure only mevalonic acid which is in equi-
librium with lactone form (not detected in our method) in mild
acid conditions; additional HIDS patient sample (especially in
crisis) analysis would be required to evaluate the feasibility of
these diagnostics with our new method.
We clinically validated our new assay by evaluating 32 dif-
ferent IEMand in total 187 sampleswith a representative number
of control samples showed that this new diagnostic approach
with z-score profiles facilitates diagnostics of the majority of
organic acidurias. Most biomarkers associated with the IEMs
included as reported in literature (Blau et al 2014) were observed
in significantly elevated levels (z-score > 3.0) in the z-score plots
for most IEM. Not all metabolites were increased to the same
Fig. 2 Summary of z-scores of critical biomarkers for 32 IEMs. Both urines from patients with an IEM as well as controls negatively tested for IEM (n =
46) were included. Red dot indicates a patient, blue circle is from a control
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extent in all patients reflecting severity of the disease and clinical
condition and/or treatment status (detailed information however
was not always available). In patients with MSUD, not all
markers were elevated in all patients; however, due to the pres-
ence of multiple biomarkers for MSUD in the metabolite panel,
this diagnosis could not bemissed. Glutaric acidwas not elevated
in all urine samples from GA I and MADD patients. With urine
organic acid analysis, 3-hydroxyglutaric acid is the diagnostic
metabolite. Glutaric acid can be completely normal in some pa-
tients but 3-hydroxyglutaric acid is pathognomonic for GA I. 3-
hydroxyglutaric acid can be hard to identify and quantitate since
it may co-elute with 2-hydroxyglutaric acid in GC-MS analyses
(Hedlund et al 2006), depending on the analytical column. In our
newly established LC-QTOF/MS assay, we could separate 2-
and 3-hydroxyglutaric acid quite well, which allows unambigu-
ous annotation and quantification of both metabolites.
All MCADD patients had abnormal z-score profiles.
MCADD diagnostics is usually based on acylcarnitine profiling
and organic acid analysis. Browning et al (2005) showed that
normal acylcarnitine levels during confirmation of abnormal
newborn screening have been encountered in some fatty acid
oxidation disorders. Our findings are therefore of extra informa-
tion on diagnostics. For these notoriously difficult IEMs several
analyses (both acylcarnitine and organic acid analysis) in differ-
ent settings (fasting and fed state) could be of added value in the
diagnostics. Eventually, enzyme or gene analysis confirms a di-
agnosis based on biochemical abnormalities.
One patient with 5-oxoprolinase deficiency (pyroglutamic
aciduria) could be easily discriminated on the basis of the z-
score for secondary causes of 5-oxoprolinuria like a certain
drug (paracetamol) (Saudubray et al 2016). The absence of
paracetamol related markers in this patient supported the
diagnosis. Other causes of 5-oxoprolinuria which include
severe burns, inborn errors of metabolism not involving
the gamma-glutamyl cycle, e.g., X-linked ornithine
transcarbamylase deficiency, urea cycle defects, tyrosinemia,
Fig. 3 Z-score profiles of some representative IEMs: isovaleric
aciduria (IVA, OMIM #243500), medium chain acyl-CoA dehydroge-
nase deficiency (MCADD, OMIM #201450), propionic aciduria (PA,
OMIM #606054), glutaric aciduria type 1 (GA I, OMIM #231670), and
methylmalonic aciduria (MMA, OMIM #251000)
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and homocystinuria were, however, not included in this
evaluation.
All these factors and representation of results as a long list
of numbers made it easy to miss a diagnosis despite reference
values. This is why we introduced z-score plots. In the broad
panel of IEMs included in this clinical validation, the z-score
plot proved to be a useful and easy to use tool for labs to
interpret the analytical results of the LC-QTOF/MS method.
The targeted biomarkers approach and number of IEM dis-
eases that can be diagnosed can be continuously expanded to
meet the complexity of IEM diagnostics. The full scan method
is flexible to include new analytes and update the method to
meet this challenge. This is part of our future work. We will
explore not only the negative but also the positive ionization
mode to cover broad chemical groups, including amino acids,
acylcarnitines, purine and pyrimidine metabolites. Eventually,
the method can be a generic metabolic screening method on the
LC-QTOF/MS platform whereby urine is analyzed as a front-
line specimen for screening of IEMs. This would provide a
valuable means to efficiently, accurately, and rapidly identify
and manage many IEMs (Campeau et al 2008).
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